<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02572765</url>
  </required_header>
  <id_info>
    <org_study_id>LMB05</org_study_id>
    <nct_id>NCT02572765</nct_id>
  </id_info>
  <brief_title>Evaluation of Splenic Metabolic Activity With 18FDG-PET in Hypertension</brief_title>
  <official_title>Evaluation of Splenic Metabolic Activity With 18FDG-PET in Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neuromed IRCCS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Neuromed IRCCS</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the splenic activation in hypertensive patients, as
      compared to normotensives, using FDG-PET/CT imaging. Moreover, the investigators will
      investigate whether the splenic metabolic activity relates to the expression of circulating
      inflammatory proteins (high-sensitivity C-reactive protein [hsCRP]), interleukin-1b (IL-1b),
      tumor necrosis factor-a (TNF-a) or to immune profiles of activated T cells.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2018</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Splenic metabolic activity</measure>
    <time_frame>At enrollment</time_frame>
    <description>18FDG uptake in splenic tissue</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Circulating pro-inflammatory markers</measure>
    <time_frame>At enrollment</time_frame>
    <description>Serum levels of pro-inflammatory cytokines</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Normotensive</arm_group_label>
    <description>Normotensive subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hypertensive</arm_group_label>
    <description>Hypertensive subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PET/CT scan</intervention_name>
    <description>PET/CT scan</description>
    <arm_group_label>Normotensive</arm_group_label>
    <arm_group_label>Hypertensive</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Total blood and serum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects will be selected from patients who will undergo FDG-PET/CT imaging of chest and
        abdomen in the Department of Nuclear Medicine of IRCCS Neuromed, accordingly to the
        following inclusion/exclusion criteria. All the enrolled patients must have an indication
        for FDG-PET/CT. Approximately 120 hypertensive and normotensive subjects of both genders
        (at least 45 per group, in order to have the appropriate statistical power) will be
        included in the study.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  absence of prior cancer diagnosis or remission from cancer at the time of FDG-PET/CT
             imaging (from at least 6 months)

          -  age ≥ 30 and ≤ 85 years

          -  absence of acute cardio/cerebrovascular disease (myocardial infarction, stroke,
             transient ischemic attack, revascularization)

          -  absence of acute or chronic inflammatory or autoimmune disease

          -  diagnosis of presence/absence of hypertension, on the basis of documented medical
             history

        Exclusion Criteria:

          -  diabetes

          -  atrial fibrillation

          -  use of anti-inflammatory drugs in the week preceding the FDG-PET/CT imaging

          -  chronic use of anti-inflammatory drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Giuseppe Lembo, MD in Cardiology</last_name>
    <phone>+39 0865.915225</phone>
    <email>lembo@neuromed.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>IRCCS Neuromed</name>
      <address>
        <city>Pozzilli</city>
        <state>(is)</state>
        <zip>86077</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 7, 2015</study_first_submitted>
  <study_first_submitted_qc>October 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 9, 2015</study_first_posted>
  <last_update_submitted>December 14, 2017</last_update_submitted>
  <last_update_submitted_qc>December 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Neuromed IRCCS</investigator_affiliation>
    <investigator_full_name>Giuseppe Lembo</investigator_full_name>
    <investigator_title>prof. Giuseppe Lembo</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

